CA2376297A1 - Procedes d'obtention de 2-methoxyestradiol tres pur - Google Patents

Procedes d'obtention de 2-methoxyestradiol tres pur Download PDF

Info

Publication number
CA2376297A1
CA2376297A1 CA002376297A CA2376297A CA2376297A1 CA 2376297 A1 CA2376297 A1 CA 2376297A1 CA 002376297 A CA002376297 A CA 002376297A CA 2376297 A CA2376297 A CA 2376297A CA 2376297 A1 CA2376297 A1 CA 2376297A1
Authority
CA
Canada
Prior art keywords
estradiol
methoxyestradiol
less
estrone
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002376297A
Other languages
English (en)
Inventor
Gregory E. Agoston
Anthony M. Treston
Jamshed H. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2376297A1 publication Critical patent/CA2376297A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention concerne du 2-méthoxyestradiol d'une pureté supérieure à 98 %, obtenu par des procédés de synthèse ou de purification. Ce 2-méthoxyestradiol très pur, exempt de constituants oestrogéniques, convient particulièrement à une utilisation clinique chez l'homme. Les procédés de purification de l'invention utilisent la chromatographie liquide-solide afin de séparer 2-ME2 des autres composés. Le milieu chromatographique est, de préférence, la silice. Le système solvant comprend un solvant non polaire, tel que le chloroforme, et un solvant polaire, tel que le méthanol.
CA002376297A 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur Abandoned CA2376297A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15029399P 1999-08-23 1999-08-23
US60/150,293 1999-08-23
PCT/US2000/023160 WO2001014405A2 (fr) 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur

Publications (1)

Publication Number Publication Date
CA2376297A1 true CA2376297A1 (fr) 2001-03-01

Family

ID=22533881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002376297A Abandoned CA2376297A1 (fr) 1999-08-23 2000-08-23 Procedes d'obtention de 2-methoxyestradiol tres pur

Country Status (5)

Country Link
EP (1) EP1206480A2 (fr)
JP (3) JP5317381B2 (fr)
AU (1) AU7572600A (fr)
CA (1) CA2376297A1 (fr)
WO (1) WO2001014405A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418876A4 (fr) * 2001-08-17 2007-07-11 Univ Pittsburgh Administration de metabolites de l'oestradiol pour le traitement ou la prevention de l'obesite, du syndrome metabolique, du diabete et de troubles vasculaires et renaux
TW200611909A (en) 2004-08-04 2006-04-16 Akzo Nobel Nv Process for the preparation 2-substituted-derivatives of estrone and estradiol
JP5317690B2 (ja) 2008-12-27 2013-10-16 株式会社東芝 メモリシステム
FR3136464A1 (fr) * 2022-06-13 2023-12-15 Industriale Chimica S.R.L. Procédé de purification de 2-méthoxyestradiol de 4-méthoxyestradiol et intermédiaires du procédé

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US6051726A (en) * 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols

Also Published As

Publication number Publication date
JP2012211132A (ja) 2012-11-01
JP2003507489A (ja) 2003-02-25
EP1206480A2 (fr) 2002-05-22
JP5317381B2 (ja) 2013-10-16
AU7572600A (en) 2001-03-19
JP2008063345A (ja) 2008-03-21
WO2001014405A3 (fr) 2002-01-24
WO2001014405A2 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
US7235540B2 (en) Methods of using 2-methoxyestradiol of high purity
CA2631748C (fr) 17.alpha.-cyanomethyl-17.beta.-hydroxy-estra-4,9-diene-3-one de purete elevee et son procede de synthese
Potter et al. A convenient, large-scale synthesis of Abiraterone acetate [3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene], a potential new drug for the treatment of prostate cancer
JP2012211132A (ja) 高純度２−メトキシエストラジオールの生成方法
AU2005321611A1 (en) Method for producing pure or enriched Q 10 coenzyme
US4145345A (en) Chromatographic purification of maytansine
CA3151465C (fr) Procede de preparation de (15a,16a,17b)-estra-1,3,5-(10)-triene-3,15,16,17-tetrol (estetrol) et intermediaires dudit procede
AU2005211579B8 (en) Compositions comprising purified 2-methoxyestradiol and methods of producing same
AU2007234536B2 (en) Compositions comprising purified 2-methoxyestradiol and methods of producing same
WO2022206870A1 (fr) Procédé de préparation et de purification du composé monométhyl auristatine e
Faraj et al. Synthesis of new steroidal 11β-substituted spirolactones
CA1153366A (fr) DERIVES D'AMMONIUM BIS- ET MONO-QUATERNAIRE DE 2, 16.beta.-DIPIPERIDINO-5.alpha.-ANDROSTANES; METHODES DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
Anderson et al. Preparation and evaluation of a hydroxycyclohexyl derivative of sephadex LH-20
CA1122590A (fr) Steroides, leur procede de preparation et leur application dans la synthese de steroides marques au tritium
RU2009146C1 (ru) Способ получения производных 19-норпрогестерона
Künzer et al. Regioselective functionalization of 3-oxygenated estra-1, 3, 5 (10)-trienes AT C-1 VIA (η6-arene) Cr (CO) 3 complexes
CN111961021B (zh) 一种香叶基黄酮a的分离纯化工艺
AU733743B2 (en) Sulfatation of estrogen mixtures
US3146231A (en) Ketals of 4, 6-androstadien-17beta-ol-3 ones and esters thereof
TR2023003649A2 (tr) (15α,16α,17β)-ESTRA-1,3,5(10)-TRİEN-3,15,16,17-TETROL MONOHİDRAT (ESTETROL MONOHİDRAT) HAZIRLANMASINA YÖNELİK PROSES
JPS5659796A (en) Purification of ursodeoxycholic acid or chenodeoxycholic acid
Tanabe et al. The synthesis of lα-methylcortisone and lα-methylhydrocortisone
Chang-Yon et al. Synthesis of 7α-hydroxycholesterol-1, 2-3H
CA2166280A1 (fr) Composes de type sterol
MXPA98003465A (en) Sulfatation of estrog mixes

Legal Events

Date Code Title Description
FZDE Dead